Novo Nordisk CEO takes aim at U.S. healthcare as he defends Ozempic pricing to Bernie Sanders
Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.
Tomas K - Moderator 
Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy. Read More
:quality(85):upscale()/2024/10/23/909/n/1922283/06a909b56719613ac8ce43.49146630_.png)
:quality(85):upscale()/2025/01/08/844/n/1922398/cde2aeac677eceef03f2d1.00424146_.jpg)
